Next Generation News and Research

RSS

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

NiTi™ Surgical Solutions, an innovative surgical device company, today announced that its ColonRing™, the first major advance in closure for gastrointestinal surgery in more than 30 years, has been used for the first time in a colorectal surgery in China. The ColonRing anastomosis device was launched in the United States in May 2008 and has been successfully applied in thousands of patients.

18 Dec 2009

Interactive health assessment system from RedBrick Health

RedBrick Health, the Health EarningsSM company, today announced the launch of its own next-generation, highly interactive health assessment. Integral to RedBrick’s Health Earnings System, the company’s new health assessment is compact, conversational and graphical, all significant departures from conventional health assessments.

18 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Aided by next-generation DNA sequencing technology, an international team of researchers has gained insights into how more than 60 carcinogens associated with cigarette smoke bind to and chemically modify human DNA, ultimately leading to cancer-causing genetic mutations.

17 Dec 2009

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced that Cancer Research UK’s Drug Development Office – the drug development arm of the world’s largest independent organization dedicated to cancer research – is standardizing on Phase Forward’s InForm™ Global Trial Management solution to support its diverse portfolio of early-stage clinical trials.

17 Dec 2009

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone payment from Pfizer Inc. The amount of the payment was not disclosed. The payment was triggered by the initiation of human clinical trials of a novel monoclonal antibody therapeutic that was optimized using Xencor technologies under a March 2009 technology license agreement.

16 Dec 2009

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of serious multi-drug-resistant infections announced today it has entered into a collaborative research agreement with Massachusetts General Hospital (MGH).

16 Dec 2009

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

When a patient has a disease that can't be treated effectively, the physician can see clearly where research is needed.

15 Dec 2009

Safe Life increases production of its A400 Series respirators

Safe Life Corp., an innovative antimicrobial company dedicated to developing novel technologies that prevent the spread of infection and disease, announced today that it is ramping production of its comfortable, breathable, A400 Series respirator to help healthcare providers and government agencies address the global shortage of N95 respirators during the H1N1 pandemic.

15 Dec 2009

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Gamma Medica-Ideas, Inc. ("GMI"), a leading developer of digital molecular imaging systems, announced today that it has signed an exclusive license and commercialization agreement with Mayo Clinic to further develop and commercialize a suite of technologies invented by a team of Mayo physicians and scientists, headed by Michael O'Connor, PhD.

15 Dec 2009

Molecular Partners closes its CHF 46 million Series B equity investment round

Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).

15 Dec 2009

US journal identifies fundamental factors behind failed EPR projects

Large-scale electronic patient record (EPR) programmes promise much but sometimes deliver little, according to a new study by UCL researchers that reviewed findings from hundreds of previous studies from all over the world.

14 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

AFP examines insecticide resistance's effect on malaria fight in Nigeria

Agence France-Presse examines the increase in insecticide-resistant mosquitoes in Nigeria - "the latest threat to combating malaria" in the country. "Nigeria, Africa's most populous country, contributes more than a quarter of the one million malaria deaths in Africa, according to official statistics," AFP writes.

10 Dec 2009

Order Online Drugs announces the launch of OrderOnlineDrugs.com

Order Online Drugs Inc. is proud to announce the launch of OrderOnlineDrugs.com (www.orderonlinedrugs.com), a next generation online Canadian pharmacy that offers brand name prescription drugs at significantly lower prices compared to local drug stores.

10 Dec 2009

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

Waters Corporation announced today that it has shipped the first units of its ground-breaking SYNAPT(TM) G2 Mass Spectrometer, first introduced at the 2009 American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia in June.

9 Dec 2009

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

Isilon Systems today announced that the Center for Inherited Disease Research (CIDR) at Johns Hopkins University is using Isilon scale-out NAS to power its leading-edge genotyping and statistical genetics services, which generate up to three terabytes of new data per day.

9 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Next Generation News and Research

NiTi Surgical Solutions' ColonRing used for the first time in a colorectal surgery in China

Interactive health assessment system from RedBrick Health

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Researchers discover new gene involved in lung cancer using DNA sequencing technology

Phase Forward’s InForm Global Trial Management solution standardized to support early-stage clinical trials

Xencor's initiation of novel monoclonal antibody human clinical trial triggers milestone payment from Pfizer

Rib-X Pharmaceuticals and MGH enter into collaborative research agreement

Lilly Endowment offers $60 million to implement the Indiana Physician Scientist Initiative

Safe Life increases production of its A400 Series respirators

Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

Molecular Partners closes its CHF 46 million Series B equity investment round

US journal identifies fundamental factors behind failed EPR projects

University of Maryland School of Nursing to spearhead new Center for Pain Studies

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

AFP examines insecticide resistance's effect on malaria fight in Nigeria

Order Online Drugs announces the launch of OrderOnlineDrugs.com

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

Specialty pharmaceutical market: Treatment patterns and product performance

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News